FDA’s January 2026 final guidance clarifies which clinical decision support software functions are excluded from device regulation. While focused on regulatory scope, the guidance matters for privacy because it helps define oversight boundaries for software that uses, analyzes, or presents patient data in clinical settings. The document is relevant to ongoing questions about digital health data use, accountability, and when federal requirements attach to software functions handling sensitive health information.
